Uncategorized

Incyte signs AI deals with Genesis Molecular AI, Edison Scientific

Published

on

Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the coming decades.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version